Meeting
2011 ASCO Annual Meeting
A phase II randomized trial of anastrozole (A) and fulvestrant (F) as consolidation therapy in postmenopausal women with advanced non-small cell lung cancer who have received first-line platinum-based chemotherapy with or without bevacizumab.
Authors
B. T. McLaughlin
University of Pittsburgh, Pittsburgh, PA
B. T. McLaughlin , S. Land , A. A. Tarhini , J. Siegfried , A. Argiris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session
Track
Special Sessions,Clinical Trials
Sub Track
Metastatic
Clinical Trial Registration Number
NCT00932152
Citation
J Clin Oncol 29: 2011 (suppl; abstr TPS212)
Abstract #
TPS212
Poster Bd #
50B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2023 ASCO Annual Meeting
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
First Author: Li Zhang
Poster
2023 ASCO Annual Meeting
Phase 2 multicenter trial of rucaparib and nivolumab as maintenance therapy following first-line platinum-based chemotherapy in patients with advanced biliary tract cancer (BTC): BilT-02.
First Author: Vaibhav Sahai
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura